If you are looking for an Oncology CRO Services, research can help you with the needs of your research. We have extensive experience with oncology CROs, and we are equipped to handle projects of any size and scope. Read on to find out more about how we can assist you with your Oncology CRO Services needs.
Interventional studies dominate the market for Oncology CRO Services
While industry-sponsored study starts have declined in the past year, there are signs that the industry is preparing to restart. The World Clinical Trials Group (WCG) projects the largest number of planned restarts in the oncology space in 2019. Despite the sluggish start of the year, WCG expects that new trials will begin at a faster pace in 2020.
As a result of an abundance of new agents and drugs, oncology trials have become more complicate. The patient burden has also increase. To combat this, sponsors are actively seeking the input of patients throughout the clinical trial design process. This includes encouraging fewer visits and the use of digital health.
Other innovations that support patient-center trials are less invasive procedures and patient concierge Oncology CRO Services. As a result, the number of industry-sponsor oncology trials in the US is expect to increase by 8% in 2020. The largest growth was seen in trials involving COVID-19, follow by trials involving a variety of types of cancer.
Biomarker validation is a critical component of oncology clinical trials
In a clinical trial, biomarkers are used as predictors of disease progression or response to a therapeutic agent. These markers can be use to select patients for further study or to assess the effectiveness of a drug. Biomarker development involves rigorous clinical and analytical validation. Ideally, these studies are conduct in a prospective setting. However, biomarker development and validation can also be conduct retrospectively by analyzing collect specimens from previously conducted trials.
Biomarker validation can help to minimize the cost to the payer. It can help to focus treatment decisions by offering more specific diagnosis. Broad panel biomarkers can also help to save the payer’s money on other diagnostic tests and therapies that may be futile.
North America leads the market of Oncology CRO Services
The contract research organization (CRO) market for oncology is dominate by North America, with a share of over 54.1% in 2021. The rise in cancer cases in the region is driving growth in this segment. Leading Oncology CRO Services companies are involve in conducting oncology clinical trials. These companies have expertise in conducting clinical trials for the entire life cycle of an oncology drug. In addition, pharmaceutical & bio-pharmaceutical firms are increasing their spending on the development of new drugs and outsourcing clinical trials.
The growth in this market has largely been driven by a number of factors, including the presence of technologically advance CROs and the highest per capita health care spending in the U.S. However, other factors such as increasing research and development, the need for more clinical trials and tighter regulatory standards are also driving growth in the region.
Read also: Oncology CRO Market Ideas and Forecast to 2031
Europe leads the market for oncology clinical trials
The oncology clinical trials CRO market is growing at a rapid pace in Europe. This region offers a variety of advantages for sponsors. For example, the healthcare system in Europe is one of the best in the world. It is home to secondary clinical research networks, which provide good infrastructure for clinical trials.
The growth in this market is due to the growing incidence of cancer and cardiovascular diseases in Europe. These diseases account for over 3.8 million deaths per year in Europe and over 1.8 million in the European Union. The increasing prevalence of these diseases is driving the market for Oncology CRO Services in this area. The end-users of these services include biotech and pharmaceutical companies, academic and research institutes, and biotechnology companies.
As a result, the region is expect to lead the market for oncology clinical trials, Oncology CRO Services over the next few years. The growth in this region is drive by increased R&D, increasing adoption of new technologies in clinical research, and strong government support for the industry. For example, the FDA has revise its guidelines for the approval of drugs for cancer, allowing researchers to conduct trials with the latest treatment options.
Asia-Pacific leads the market for Oncology CRO Services
The Asia-Pacific region is a major source of research and clinical trials in Oncology CRO Services. The population of this region is large and there are significant needs for treatments in this region. Asia-Pacific is also home to several important research areas in oncology, including immune-oncology and cancer immunotherapy. China, for example, is an important country for adoptive cell transfer studies. This treatment has initially been used in hematological cancers, but is expanding to solid tumors.
The region offers favorable supply and cost factors for Oncology CRO Services. Costs are lower than in other regions of the world. Clinical trial sites in APAC are also more accessible and have a larger patient pool, which reduces recruitment time. Furthermore, the region also has the largest number of Contract Research Organization making it a great choice for biotechnology firms seeking oncology clinical trials.